JP2006507225A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006507225A5 JP2006507225A5 JP2004515703A JP2004515703A JP2006507225A5 JP 2006507225 A5 JP2006507225 A5 JP 2006507225A5 JP 2004515703 A JP2004515703 A JP 2004515703A JP 2004515703 A JP2004515703 A JP 2004515703A JP 2006507225 A5 JP2006507225 A5 JP 2006507225A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- glutamate receptor
- metabotropic glutamate
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 claims 12
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims 12
- 239000005557 antagonist Substances 0.000 claims 12
- 230000003287 optical effect Effects 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 5
- 208000006673 asthma Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 2
- 210000000111 lower esophageal sphincter Anatomy 0.000 claims 2
- 239000003512 metabotropic receptor antagonist Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000010992 reflux Methods 0.000 claims 2
- 230000001052 transient effect Effects 0.000 claims 2
- NEWKHUASLBMWRE-UHFFFAOYSA-N 2-methyl-6-(phenylethynyl)pyridine Chemical group CC1=CC=CC(C#CC=2C=CC=CC=2)=N1 NEWKHUASLBMWRE-UHFFFAOYSA-N 0.000 claims 1
- PKDHDJBNEKXCBI-UHFFFAOYSA-N 2-methyl-6-(phenylethynyl)pyridine hydrochloride Chemical group Cl.CC1=CC=CC(C#CC=2C=CC=CC=2)=N1 PKDHDJBNEKXCBI-UHFFFAOYSA-N 0.000 claims 1
- NBFUGBSVJORKJO-UHFFFAOYSA-N 3-[3-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-5-yl]-5-(methoxymethyl)benzonitrile Chemical group COCC1=CC(C#N)=CC(C=2ON=C(N=2)C=2N=CC(F)=CC=2)=C1 NBFUGBSVJORKJO-UHFFFAOYSA-N 0.000 claims 1
- RBSPCALDSNXWEP-UHFFFAOYSA-N 3-fluoro-5-[3-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-5-yl]benzonitrile Chemical group N1=CC(F)=CC=C1C1=NOC(C=2C=C(C=C(F)C=2)C#N)=N1 RBSPCALDSNXWEP-UHFFFAOYSA-N 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 206010067171 Regurgitation Diseases 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 208000037824 growth disorder Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0201943A SE0201943D0 (sv) | 2002-06-20 | 2002-06-20 | New use |
| PCT/US2003/016223 WO2004000316A1 (en) | 2002-06-20 | 2003-06-19 | Use of mglur5 antagonists for the treatment of gerd |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010268162A Division JP2011068669A (ja) | 2002-06-20 | 2010-12-01 | Ｇｅｒｄの治療のためのｍｇｌｕｒ５アンタゴニストの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006507225A JP2006507225A (ja) | 2006-03-02 |
| JP2006507225A5 true JP2006507225A5 (enExample) | 2006-07-20 |
| JP4683920B2 JP4683920B2 (ja) | 2011-05-18 |
Family
ID=20288301
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004515703A Expired - Fee Related JP4683920B2 (ja) | 2002-06-20 | 2003-06-19 | Ｇｅｒｄの治療のためのｍｇｌｕｒ５アンタゴニストの使用 |
| JP2010268162A Pending JP2011068669A (ja) | 2002-06-20 | 2010-12-01 | Ｇｅｒｄの治療のためのｍｇｌｕｒ５アンタゴニストの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010268162A Pending JP2011068669A (ja) | 2002-06-20 | 2010-12-01 | Ｇｅｒｄの治療のためのｍｇｌｕｒ５アンタゴニストの使用 |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1513525B1 (enExample) |
| JP (2) | JP4683920B2 (enExample) |
| CN (1) | CN100430056C (enExample) |
| AT (1) | ATE395059T1 (enExample) |
| AU (1) | AU2003241585B2 (enExample) |
| BR (1) | BR0311759A (enExample) |
| CA (1) | CA2489730C (enExample) |
| CY (1) | CY1107954T1 (enExample) |
| DE (1) | DE60320990D1 (enExample) |
| DK (1) | DK1513525T3 (enExample) |
| ES (1) | ES2304510T3 (enExample) |
| IL (1) | IL165138A0 (enExample) |
| IS (1) | IS7654A (enExample) |
| MX (1) | MXPA04012659A (enExample) |
| NO (1) | NO20050154L (enExample) |
| NZ (1) | NZ536559A (enExample) |
| PL (1) | PL372186A1 (enExample) |
| PT (1) | PT1513525E (enExample) |
| RU (1) | RU2324484C2 (enExample) |
| SE (1) | SE0201943D0 (enExample) |
| SI (1) | SI1513525T1 (enExample) |
| UA (1) | UA81627C2 (enExample) |
| WO (1) | WO2004000316A1 (enExample) |
| ZA (1) | ZA200409908B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7964609B2 (en) | 2002-06-20 | 2011-06-21 | Astrazeneca Ab | Use of mGluR5 antagonists for the treatment of gerd |
| SE0303418D0 (sv) * | 2003-12-17 | 2003-12-17 | Astrazeneca Ab | New use 1 |
| WO2005060971A1 (en) * | 2003-12-18 | 2005-07-07 | Astrazeneca Ab | Treatment of reflux-related diseases |
| WO2005060961A2 (en) * | 2003-12-18 | 2005-07-07 | Astrazeneca Ab | Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd) |
| WO2005077368A2 (en) * | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| WO2005077345A1 (en) * | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| CN1918154A (zh) * | 2004-02-18 | 2007-02-21 | 阿斯利康(瑞典)有限公司 | 多杂环化合物及其作为代谢型谷氨酸受体拮抗剂的用途 |
| RU2006128445A (ru) * | 2004-02-18 | 2008-03-27 | Астразенека Аб (Se) | Ацетилиновые пиперазиновые соединения и их применение в качестве антагонистов метаботропных глутаматных рецепторов |
| GB0514296D0 (en) * | 2005-07-12 | 2005-08-17 | Novartis Ag | Organic compounds |
| SI2001849T1 (sl) * | 2006-03-29 | 2015-02-27 | F. Hoffmann-La Roche Ag | Derivati piridina in pirimidina kot antagonisti mglur2 |
| KR20090061041A (ko) | 2006-09-11 | 2009-06-15 | 노파르티스 아게 | 대사성 글루타메이트 수용체의 조절제로서의 니코틴산 유도체 |
| JP2008245225A (ja) * | 2007-03-29 | 2008-10-09 | Kddi Corp | 波長パス経路決定装置、波長パス設定制御システム及びプログラム |
| WO2009024491A1 (en) * | 2007-08-20 | 2009-02-26 | F. Hoffmann-La Roche Ag | Use of mglur5 antagonists for the treatment of gerd |
| EP2826478A1 (en) | 2008-06-30 | 2015-01-21 | Novartis AG | Combinations comprising mglur modulators for the treatment of parkinson's disease |
| WO2011009890A2 (en) | 2009-07-23 | 2011-01-27 | Novartis Ag | Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives |
| JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
| EP2490691A1 (en) | 2009-10-20 | 2012-08-29 | Novartis AG | Use of 1h-quinazoline-2,4-diones |
| RU2013103001A (ru) | 2010-06-24 | 2014-07-27 | Новартис Аг | Применение 1н-хиназолин-2,4-дионов |
| US20140171448A1 (en) | 2011-01-27 | 2014-06-19 | Novartis Ag | Use of nicotinic acetylcholine receptor alpha 7 activators |
| WO2013036224A1 (en) | 2011-09-07 | 2013-03-14 | Novartis Ag | Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy |
| BR112015016994A8 (pt) | 2013-01-15 | 2018-01-23 | Novartis Ag | uso de agonistas do receptor alfa 7 nicotínico de acetilcolina |
| WO2014111837A1 (en) | 2013-01-15 | 2014-07-24 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
| US20220387410A1 (en) * | 2019-11-05 | 2022-12-08 | Claes Thulin | 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of surmenage in a mammal |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU594424B2 (en) * | 1986-01-03 | 1990-03-08 | University Of Melbourne, The | Gastro-oesophageal reflux composition |
| SE9603408D0 (sv) * | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
| JP2002515448A (ja) * | 1998-05-15 | 2002-05-28 | アフトン・コーポレーシヨン | 食道逆流病の処置法 |
| RU2144331C1 (ru) * | 1998-11-05 | 2000-01-20 | Московский НИИ уха, горла и носа | Способ лечения хронического гиперпластического ларингита |
| CZ2002599A3 (cs) * | 1999-08-19 | 2002-06-12 | Nps Pharmaceuticals Inc. | Heteropolycyklické sloučeniny a jejich pouľití jako antagonistů metabotropního receptoru glutamátu |
| US7115630B2 (en) * | 2000-10-02 | 2006-10-03 | Janssen Pharmaceutica N.V. | Metabotropic glutamate receptor antagonists |
-
2002
- 2002-06-20 SE SE0201943A patent/SE0201943D0/xx unknown
-
2003
- 2003-06-19 DK DK03731333T patent/DK1513525T3/da active
- 2003-06-19 ES ES03731333T patent/ES2304510T3/es not_active Expired - Lifetime
- 2003-06-19 PL PL03372186A patent/PL372186A1/xx not_active Application Discontinuation
- 2003-06-19 PT PT03731333T patent/PT1513525E/pt unknown
- 2003-06-19 MX MXPA04012659A patent/MXPA04012659A/es not_active Application Discontinuation
- 2003-06-19 RU RU2005101411/15A patent/RU2324484C2/ru not_active IP Right Cessation
- 2003-06-19 SI SI200331220T patent/SI1513525T1/sl unknown
- 2003-06-19 DE DE60320990T patent/DE60320990D1/de not_active Expired - Lifetime
- 2003-06-19 JP JP2004515703A patent/JP4683920B2/ja not_active Expired - Fee Related
- 2003-06-19 WO PCT/US2003/016223 patent/WO2004000316A1/en not_active Ceased
- 2003-06-19 UA UA20041210177A patent/UA81627C2/ru unknown
- 2003-06-19 AU AU2003241585A patent/AU2003241585B2/en not_active Ceased
- 2003-06-19 NZ NZ536559A patent/NZ536559A/en not_active IP Right Cessation
- 2003-06-19 CN CNB038141760A patent/CN100430056C/zh not_active Expired - Fee Related
- 2003-06-19 EP EP03731333A patent/EP1513525B1/en not_active Expired - Lifetime
- 2003-06-19 AT AT03731333T patent/ATE395059T1/de active
- 2003-06-19 BR BR0311759-6A patent/BR0311759A/pt not_active IP Right Cessation
- 2003-06-19 CA CA2489730A patent/CA2489730C/en not_active Expired - Fee Related
-
2004
- 2004-11-10 IL IL16513804A patent/IL165138A0/xx unknown
- 2004-12-07 ZA ZA200409908A patent/ZA200409908B/en unknown
-
2005
- 2005-01-11 NO NO20050154A patent/NO20050154L/no not_active Application Discontinuation
- 2005-01-19 IS IS7654A patent/IS7654A/is unknown
-
2008
- 2008-05-21 CY CY20081100527T patent/CY1107954T1/el unknown
-
2010
- 2010-12-01 JP JP2010268162A patent/JP2011068669A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006507225A5 (enExample) | ||
| CA2489730A1 (en) | Use of mglur5 antagonists for the treatment of gerd | |
| JP2017528507A5 (enExample) | ||
| US20020019421A1 (en) | Compositions and therapy for substance addiction | |
| CN103458690B (zh) | 治疗肺动脉高压的组合物和方法 | |
| JP5907975B2 (ja) | 運動障害の治療のためのセロトニン受容体アゴニストの組み合わせ | |
| JP5796959B2 (ja) | 関節炎における痛みの治療のためのタペンタドール | |
| JP2009542702A5 (enExample) | ||
| WO2006059108A3 (en) | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES | |
| JP2008515905A5 (enExample) | ||
| JP2009542699A5 (enExample) | ||
| JP2005502643A5 (enExample) | ||
| JP2010512414A5 (enExample) | ||
| EP2942082A3 (en) | A2A receptor antogonists for use in the treatment of movement disorders | |
| JP2019525948A5 (enExample) | ||
| JP2019512495A5 (enExample) | ||
| JP2009532438A5 (enExample) | ||
| US20060293309A1 (en) | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors | |
| JP2006524203A5 (enExample) | ||
| JP2012518019A5 (enExample) | ||
| Pelaia et al. | Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD | |
| CN113453683A (zh) | 运动障碍的治疗 | |
| JP2012528824A5 (enExample) | ||
| WO2005011594A3 (en) | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease | |
| JP2011500589A5 (enExample) |